bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
81 hedge funds and large institutions have $378M invested in bluebird bio in 2013 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 32 increasing their positions, 16 reducing their positions, and 12 closing their positions.
117% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 12
100% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 16
60% more capital invested
Capital invested by funds: $236M → $378M (+$142M)
21% more funds holding
Funds holding: 67 → 81 (+14)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$43.1M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$34.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$10.4M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$5.8M |
| 5 |
FAM
Fred Alger Management
New York
|
+$5.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$6M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.63M |
| 3 |
PC
PointState Capital
New York
|
-$2.16M |
| 4 |
QF
QVT Financial
New York
|
-$2.02M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$876K |
BLUE Hedge Fund Activity: Q4 2013 in Review
81 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q4 2013, worth a combined $378M — up 60% from $236M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new BLUE positions and 12 closed out — a net gain of 14 holders — while 32 added to existing stakes and 16 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $43.1M. The largest seller was OrbiMed, exiting entirely with an estimated $6M sold.
- 81 institutional investors held bluebird bio (BLUE) as of Q4 2013, up from 67 in Q3 2013.
- Funds reported $378M of bluebird bio stock for Q4 2013, up 60% quarter-over-quarter.
- 26 funds opened new bluebird bio positions in Q4 2013 and 12 closed out, a net change of +14 holders.
- The largest bluebird bio buyer in Q4 2013 was Fidelity Investments, an estimated $43.1M added.
- The largest bluebird bio seller in Q4 2013 was OrbiMed, an estimated $6M sold.
Based on aggregated 13F filings for Q4 2013.